Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Pilot Evaluation of 124I-Iodo-Azomycin Galacto-Pyranoside (*IAZGP) Positron Emission Tomography (PET) in the Imaging of Hypoxic Tumors
Pilot Evaluation of 124I-Iodo-Azomycin Galacto-Pyranoside (*IAZGP) Positron Emission Tomography (PET) in the Imaging of Hypoxic Tumors
Status: Enrolling
Updated:  12/23/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Pilot Evaluation of 124I-Iodo-Azomycin Galacto-Pyranoside (*IAZGP) Positron Emission Tomography (PET) in the Imaging of Hypoxic Tumors
Pilot Evaluation of 124I-Iodo-Azomycin Galacto-Pyranoside (*IAZGP) Positron Emission Tomography (PET) in the Imaging of Hypoxic Tumors
Status: Enrolling
Updated: 12/23/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Patient Preference Survey for Radiation Oncologists
How Can Radiation Oncologists Better Serve Their Patients? A Randomized Study to Determine Whether Radiation Oncologists Can Improve Patient Satisfaction by Attempting to Meet Their Patients' Preferences
Status: Enrolling
Updated:  12/23/2015
UPMC Cancer Centers
mi
from
Pittsburgh, PA
Patient Preference Survey for Radiation Oncologists
How Can Radiation Oncologists Better Serve Their Patients? A Randomized Study to Determine Whether Radiation Oncologists Can Improve Patient Satisfaction by Attempting to Meet Their Patients' Preferences
Status: Enrolling
Updated: 12/23/2015
UPMC Cancer Centers
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Biodistribution and Dosimetry of Serial PET Imaging With Ga-68 Labeled F(ab') 2- Trastuzumab
Biodistribution and Dosimetry of Serial PET Imaging With Ga-68 Labeled F(ab') 2- Trastuzumab
Status: Enrolling
Updated:  12/23/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Biodistribution and Dosimetry of Serial PET Imaging With Ga-68 Labeled F(ab') 2- Trastuzumab
Biodistribution and Dosimetry of Serial PET Imaging With Ga-68 Labeled F(ab') 2- Trastuzumab
Status: Enrolling
Updated: 12/23/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Evaluating Renal Masses Using Ultrasound Intravenous Microbubble Contrast
Evaluation of Renal Masses Using Ultrasound Intravenous Microbubble Contrast
Status: Enrolling
Updated:  12/23/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Evaluating Renal Masses Using Ultrasound Intravenous Microbubble Contrast
Evaluation of Renal Masses Using Ultrasound Intravenous Microbubble Contrast
Status: Enrolling
Updated: 12/23/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
SBRT + TACE for Primary Hepatocellular Carcinoma
A Study of Stereotactic Body Radiation Therapy (SBRT) in Combination With Cisplatin Transcatheter Arterial Chemoembolization (TACE) for Primary Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/23/2015
UPMC Shadyside Radiation Oncology
mi
from
Pittsburgh, PA
SBRT + TACE for Primary Hepatocellular Carcinoma
A Study of Stereotactic Body Radiation Therapy (SBRT) in Combination With Cisplatin Transcatheter Arterial Chemoembolization (TACE) for Primary Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/23/2015
UPMC Shadyside Radiation Oncology
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
SBRT + TACE for Primary Hepatocellular Carcinoma
A Study of Stereotactic Body Radiation Therapy (SBRT) in Combination With Cisplatin Transcatheter Arterial Chemoembolization (TACE) for Primary Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/23/2015
UPMC Presbyterian/Montifore
mi
from
Pittsburgh, PA
SBRT + TACE for Primary Hepatocellular Carcinoma
A Study of Stereotactic Body Radiation Therapy (SBRT) in Combination With Cisplatin Transcatheter Arterial Chemoembolization (TACE) for Primary Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/23/2015
UPMC Presbyterian/Montifore
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
SBRT + TACE for Primary Hepatocellular Carcinoma
A Study of Stereotactic Body Radiation Therapy (SBRT) in Combination With Cisplatin Transcatheter Arterial Chemoembolization (TACE) for Primary Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/23/2015
Hillman Cancer Center
mi
from
Pittsburgh, PA
SBRT + TACE for Primary Hepatocellular Carcinoma
A Study of Stereotactic Body Radiation Therapy (SBRT) in Combination With Cisplatin Transcatheter Arterial Chemoembolization (TACE) for Primary Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/23/2015
Hillman Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
SBRT + TACE for Primary Hepatocellular Carcinoma
A Study of Stereotactic Body Radiation Therapy (SBRT) in Combination With Cisplatin Transcatheter Arterial Chemoembolization (TACE) for Primary Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated:  12/23/2015
Upmc Cancer Pavilion
mi
from
Pittsburgh, PA
SBRT + TACE for Primary Hepatocellular Carcinoma
A Study of Stereotactic Body Radiation Therapy (SBRT) in Combination With Cisplatin Transcatheter Arterial Chemoembolization (TACE) for Primary Hepatocellular Carcinoma (HCC)
Status: Enrolling
Updated: 12/23/2015
Upmc Cancer Pavilion
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Study of RO4929097 in Advanced Platinum Resistant Ovarian Cancer
Status: Enrolling
Updated:  12/23/2015
Tower Cancer Research Foundation
mi
from
Beverly Hills, CA
RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Study of RO4929097 in Advanced Platinum Resistant Ovarian Cancer
Status: Enrolling
Updated: 12/23/2015
Tower Cancer Research Foundation
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Study of RO4929097 in Advanced Platinum Resistant Ovarian Cancer
Status: Enrolling
Updated:  12/23/2015
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Study of RO4929097 in Advanced Platinum Resistant Ovarian Cancer
Status: Enrolling
Updated: 12/23/2015
City of Hope Comprehensive Cancer Center
mi
from
Duarte, CA
Click here to add this to my saved trials
RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Study of RO4929097 in Advanced Platinum Resistant Ovarian Cancer
Status: Enrolling
Updated:  12/23/2015
Los Angeles County-USC Medical Center
mi
from
Los Angeles, CA
RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Study of RO4929097 in Advanced Platinum Resistant Ovarian Cancer
Status: Enrolling
Updated: 12/23/2015
Los Angeles County-USC Medical Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Study of RO4929097 in Advanced Platinum Resistant Ovarian Cancer
Status: Enrolling
Updated:  12/23/2015
University of California-Davis Comprehensive Cancer Ctr
mi
from
Sacramento, CA
RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Study of RO4929097 in Advanced Platinum Resistant Ovarian Cancer
Status: Enrolling
Updated: 12/23/2015
University of California-Davis Comprehensive Cancer Ctr
mi
from
Sacramento, CA
Click here to add this to my saved trials
RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Study of RO4929097 in Advanced Platinum Resistant Ovarian Cancer
Status: Enrolling
Updated:  12/23/2015
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Study of RO4929097 in Advanced Platinum Resistant Ovarian Cancer
Status: Enrolling
Updated: 12/23/2015
University of Chicago Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Study of RO4929097 in Advanced Platinum Resistant Ovarian Cancer
Status: Enrolling
Updated:  12/23/2015
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Study of RO4929097 in Advanced Platinum Resistant Ovarian Cancer
Status: Enrolling
Updated: 12/23/2015
Penn State Milton S. Hershey Medical Center
mi
from
Hershey, PA
Click here to add this to my saved trials
RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Study of RO4929097 in Advanced Platinum Resistant Ovarian Cancer
Status: Enrolling
Updated:  12/23/2015
Juravinski Cancer Centre at Hamilton Health Sciences
mi
from
Hamilton,
RO4929097 in Treating Patients With Recurrent and/or Metastatic Epithelial Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer
A Phase II Study of RO4929097 in Advanced Platinum Resistant Ovarian Cancer
Status: Enrolling
Updated: 12/23/2015
Juravinski Cancer Centre at Hamilton Health Sciences
mi
from
Hamilton,
Click here to add this to my saved trials
Safety Study of Modified Vaccinia Virus to Cancer
A Phase I Dose-escalation Trial of vvDD-CDSR (Double-deleted Vaccinia Virus Plus CD/ SMR) Administered by Intratumoral Injection or Intravenous Injection
Status: Enrolling
Updated:  12/23/2015
University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Safety Study of Modified Vaccinia Virus to Cancer
A Phase I Dose-escalation Trial of vvDD-CDSR (Double-deleted Vaccinia Virus Plus CD/ SMR) Administered by Intratumoral Injection or Intravenous Injection
Status: Enrolling
Updated: 12/23/2015
University of Pittsburgh Cancer Institute
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Positron Emission Tomography Before Surgery in Evaluating Women With Primary or Recurrent Breast Cancer
A Pilot Study To Assess The Utility Of 18F-Fluorodeoxyglucose Positron Emission Tomography (PET) In The Pre-Operative Evaluation Of Patients With Primary And Recurrent Breast Carcinoma
Status: Enrolling
Updated:  12/23/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Positron Emission Tomography Before Surgery in Evaluating Women With Primary or Recurrent Breast Cancer
A Pilot Study To Assess The Utility Of 18F-Fluorodeoxyglucose Positron Emission Tomography (PET) In The Pre-Operative Evaluation Of Patients With Primary And Recurrent Breast Carcinoma
Status: Enrolling
Updated: 12/23/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
PET Scans in Patients With Locally Advanced Breast Cancer
Positron Emitter I-124-Iododeoxyuridine to Follow DNA Metabolism on Scans and in Tumor Samples in Advanced Breast Cancer: Comparison to 18-F-2-Fluoro-2-Deoxy-(D)-Glucose, as a Tracer for Glycolysis
Status: Enrolling
Updated:  12/23/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
PET Scans in Patients With Locally Advanced Breast Cancer
Positron Emitter I-124-Iododeoxyuridine to Follow DNA Metabolism on Scans and in Tumor Samples in Advanced Breast Cancer: Comparison to 18-F-2-Fluoro-2-Deoxy-(D)-Glucose, as a Tracer for Glycolysis
Status: Enrolling
Updated: 12/23/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
MUC1 Vaccine in Conjunction With Poly-ICLC in Patients With Recurrent and/or Advanced Prostate Cancer
A Pilot Dose Finding Study of MUC1 Vaccine in Conjunction With Poly-ICLC (Polyinosinic-polycytidylic Acid Stabilized With Polylysine and Carboxymethylcellulose) or HiltonolTM in Patients With Recurrent and/or Advanced Prostate Cancer
Status: Enrolling
Updated:  12/23/2015
Hillman Cancer Center
mi
from
Pittsburgh, PA
MUC1 Vaccine in Conjunction With Poly-ICLC in Patients With Recurrent and/or Advanced Prostate Cancer
A Pilot Dose Finding Study of MUC1 Vaccine in Conjunction With Poly-ICLC (Polyinosinic-polycytidylic Acid Stabilized With Polylysine and Carboxymethylcellulose) or HiltonolTM in Patients With Recurrent and/or Advanced Prostate Cancer
Status: Enrolling
Updated: 12/23/2015
Hillman Cancer Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Gene Expression Following Short Term Exposure to Neoadjuvant Endocrine Therapy in Invasive Breast Cancer
Analysis of Gene Expression Following Short Term Exposure to Neoadjuvant Endocrine Therapy in Invasive Breast Cancer
Status: Enrolling
Updated:  12/23/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Gene Expression Following Short Term Exposure to Neoadjuvant Endocrine Therapy in Invasive Breast Cancer
Analysis of Gene Expression Following Short Term Exposure to Neoadjuvant Endocrine Therapy in Invasive Breast Cancer
Status: Enrolling
Updated: 12/23/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
The Use of Breathing Synchronized CT and PET Scans in Radiation Therapy Treatment Planning
The Use of Breathing Synchronized CT and PET Scans in Radiation Therapy Treatment Planning
Status: Enrolling
Updated:  12/23/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
The Use of Breathing Synchronized CT and PET Scans in Radiation Therapy Treatment Planning
The Use of Breathing Synchronized CT and PET Scans in Radiation Therapy Treatment Planning
Status: Enrolling
Updated: 12/23/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
PET Imaging With Cu-64 Labeled Trastuzumab in HER2+ Metastatic Breast Cancer
Pilot Trial of PET Imaging With Cu-64 Labeled Trastuzumab in HER2+ Metastatic Breast Cancer
Status: Enrolling
Updated:  12/23/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
PET Imaging With Cu-64 Labeled Trastuzumab in HER2+ Metastatic Breast Cancer
Pilot Trial of PET Imaging With Cu-64 Labeled Trastuzumab in HER2+ Metastatic Breast Cancer
Status: Enrolling
Updated: 12/23/2015
Memorial Sloan Kettering Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms
Phase III Randomized Controlled Trial of a Collaborative Care Intervention to Manage Cancer Related Symptoms in Patients Diagnosed With Hepatobiliary Carcinoma
Status: Enrolling
Updated:  12/23/2015
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Comprehensive Electronic Cancer Support System for the Treatment of Cancer Related Symptoms
Phase III Randomized Controlled Trial of a Collaborative Care Intervention to Manage Cancer Related Symptoms in Patients Diagnosed With Hepatobiliary Carcinoma
Status: Enrolling
Updated: 12/23/2015
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib
An Exploratory, Phase II Trial to Determine the Association of Lapatinib Induced Fluoropyrimidine Gene Changes With Efficacy Parameters of Lapatinib and Capecitabine in First Line Gastric Cancer
Status: Enrolling
Updated:  12/24/2015
GSK Investigational Site
mi
from
Loma Linda, CA
Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib
An Exploratory, Phase II Trial to Determine the Association of Lapatinib Induced Fluoropyrimidine Gene Changes With Efficacy Parameters of Lapatinib and Capecitabine in First Line Gastric Cancer
Status: Enrolling
Updated: 12/24/2015
GSK Investigational Site
mi
from
Loma Linda, CA
Click here to add this to my saved trials
Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib
An Exploratory, Phase II Trial to Determine the Association of Lapatinib Induced Fluoropyrimidine Gene Changes With Efficacy Parameters of Lapatinib and Capecitabine in First Line Gastric Cancer
Status: Enrolling
Updated:  12/24/2015
GSK Investigational Site
mi
from
Los Angeles, CA
Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib
An Exploratory, Phase II Trial to Determine the Association of Lapatinib Induced Fluoropyrimidine Gene Changes With Efficacy Parameters of Lapatinib and Capecitabine in First Line Gastric Cancer
Status: Enrolling
Updated: 12/24/2015
GSK Investigational Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib
An Exploratory, Phase II Trial to Determine the Association of Lapatinib Induced Fluoropyrimidine Gene Changes With Efficacy Parameters of Lapatinib and Capecitabine in First Line Gastric Cancer
Status: Enrolling
Updated:  12/24/2015
GSK Investigational Site
mi
from
Washington,
Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib
An Exploratory, Phase II Trial to Determine the Association of Lapatinib Induced Fluoropyrimidine Gene Changes With Efficacy Parameters of Lapatinib and Capecitabine in First Line Gastric Cancer
Status: Enrolling
Updated: 12/24/2015
GSK Investigational Site
mi
from
Washington,
Click here to add this to my saved trials
Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib
An Exploratory, Phase II Trial to Determine the Association of Lapatinib Induced Fluoropyrimidine Gene Changes With Efficacy Parameters of Lapatinib and Capecitabine in First Line Gastric Cancer
Status: Enrolling
Updated:  12/24/2015
GSK Investigational Site
mi
from
Shreveport, LA
Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib
An Exploratory, Phase II Trial to Determine the Association of Lapatinib Induced Fluoropyrimidine Gene Changes With Efficacy Parameters of Lapatinib and Capecitabine in First Line Gastric Cancer
Status: Enrolling
Updated: 12/24/2015
GSK Investigational Site
mi
from
Shreveport, LA
Click here to add this to my saved trials
Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib
An Exploratory, Phase II Trial to Determine the Association of Lapatinib Induced Fluoropyrimidine Gene Changes With Efficacy Parameters of Lapatinib and Capecitabine in First Line Gastric Cancer
Status: Enrolling
Updated:  12/24/2015
GSK Investigational Site
mi
from
Ann Arbor, MI
Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib
An Exploratory, Phase II Trial to Determine the Association of Lapatinib Induced Fluoropyrimidine Gene Changes With Efficacy Parameters of Lapatinib and Capecitabine in First Line Gastric Cancer
Status: Enrolling
Updated: 12/24/2015
GSK Investigational Site
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib
An Exploratory, Phase II Trial to Determine the Association of Lapatinib Induced Fluoropyrimidine Gene Changes With Efficacy Parameters of Lapatinib and Capecitabine in First Line Gastric Cancer
Status: Enrolling
Updated:  12/24/2015
GSK Investigational Site
mi
from
Southgate, MI
Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib
An Exploratory, Phase II Trial to Determine the Association of Lapatinib Induced Fluoropyrimidine Gene Changes With Efficacy Parameters of Lapatinib and Capecitabine in First Line Gastric Cancer
Status: Enrolling
Updated: 12/24/2015
GSK Investigational Site
mi
from
Southgate, MI
Click here to add this to my saved trials
Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib
An Exploratory, Phase II Trial to Determine the Association of Lapatinib Induced Fluoropyrimidine Gene Changes With Efficacy Parameters of Lapatinib and Capecitabine in First Line Gastric Cancer
Status: Enrolling
Updated:  12/24/2015
GSK Investigational Site
mi
from
Jefferson City, MO
Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib
An Exploratory, Phase II Trial to Determine the Association of Lapatinib Induced Fluoropyrimidine Gene Changes With Efficacy Parameters of Lapatinib and Capecitabine in First Line Gastric Cancer
Status: Enrolling
Updated: 12/24/2015
GSK Investigational Site
mi
from
Jefferson City, MO
Click here to add this to my saved trials
Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib
An Exploratory, Phase II Trial to Determine the Association of Lapatinib Induced Fluoropyrimidine Gene Changes With Efficacy Parameters of Lapatinib and Capecitabine in First Line Gastric Cancer
Status: Enrolling
Updated:  12/24/2015
GSK Investigational Site
mi
from
Dallas, TX
Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib
An Exploratory, Phase II Trial to Determine the Association of Lapatinib Induced Fluoropyrimidine Gene Changes With Efficacy Parameters of Lapatinib and Capecitabine in First Line Gastric Cancer
Status: Enrolling
Updated: 12/24/2015
GSK Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib
An Exploratory, Phase II Trial to Determine the Association of Lapatinib Induced Fluoropyrimidine Gene Changes With Efficacy Parameters of Lapatinib and Capecitabine in First Line Gastric Cancer
Status: Enrolling
Updated:  12/24/2015
GSK Investigational Site
mi
from
Montreal,
Study For Patients With Untreated Gastric Cancer Who Will Receive Capecitabine And Lapatinib
An Exploratory, Phase II Trial to Determine the Association of Lapatinib Induced Fluoropyrimidine Gene Changes With Efficacy Parameters of Lapatinib and Capecitabine in First Line Gastric Cancer
Status: Enrolling
Updated: 12/24/2015
GSK Investigational Site
mi
from
Montreal,
Click here to add this to my saved trials
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated:  12/28/2015
City of Hope National Medical Center
mi
from
Duarte, CA
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated: 12/28/2015
City of Hope National Medical Center
mi
from
Duarte, CA
Click here to add this to my saved trials
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated:  12/28/2015
Columbia University Medical Center - Herbert Irving Comprehensive Cancer Center
mi
from
New York, NY
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated: 12/28/2015
Columbia University Medical Center - Herbert Irving Comprehensive Cancer Center
mi
from
New York, NY
Click here to add this to my saved trials
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated:  12/28/2015
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated: 12/28/2015
H. Lee Moffitt Cancer Center & Research Institute
mi
from
Tampa, FL
Click here to add this to my saved trials
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated:  12/28/2015
Mary Crowley Medical Research Center
mi
from
Dallas, TX
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated: 12/28/2015
Mary Crowley Medical Research Center
mi
from
Dallas, TX
Click here to add this to my saved trials
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated:  12/28/2015
Medical University of South Carolina Hollings Cancer Center
mi
from
Charleston, SC
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated: 12/28/2015
Medical University of South Carolina Hollings Cancer Center
mi
from
Charleston, SC
Click here to add this to my saved trials
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated:  12/28/2015
Northwestern University - Robert H Lurie Comprehensive Cancer Center
mi
from
Chicago, IL
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated: 12/28/2015
Northwestern University - Robert H Lurie Comprehensive Cancer Center
mi
from
Chicago, IL
Click here to add this to my saved trials
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated:  12/28/2015
Swedish Cancer Institute
mi
from
Seattle, WA
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated: 12/28/2015
Swedish Cancer Institute
mi
from
Seattle, WA
Click here to add this to my saved trials
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated:  12/28/2015
The Jones Clinic, PC
mi
from
Germantown, TN
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated: 12/28/2015
The Jones Clinic, PC
mi
from
Germantown, TN
Click here to add this to my saved trials
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated:  12/28/2015
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated: 12/28/2015
Ohio State University Comprehensive Cancer Center
mi
from
Columbus, OH
Click here to add this to my saved trials
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated:  12/28/2015
UC Davis Comprehensive Cancer Center
mi
from
Sacramento, CA
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated: 12/28/2015
UC Davis Comprehensive Cancer Center
mi
from
Sacramento, CA
Click here to add this to my saved trials
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated:  12/28/2015
University of Louisville/James Graham Brown Cancer Center
mi
from
Louisville, KY
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated: 12/28/2015
University of Louisville/James Graham Brown Cancer Center
mi
from
Louisville, KY
Click here to add this to my saved trials
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated:  12/28/2015
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated: 12/28/2015
University of Texas Southwestern Medical Center
mi
from
Dallas, TX
Click here to add this to my saved trials
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated:  12/28/2015
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated: 12/28/2015
U.S.C./Norris Comprehensive Cancer Center
mi
from
Los Angeles, CA
Click here to add this to my saved trials
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated:  12/28/2015
UW Carbone Cancer Center
mi
from
Madison, WI
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated: 12/28/2015
UW Carbone Cancer Center
mi
from
Madison, WI
Click here to add this to my saved trials
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated:  12/28/2015
Fox Chase Cancer Center
mi
from
Philadelphia, PA
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated: 12/28/2015
Fox Chase Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated:  12/28/2015
University of British Columbia and Vancouver General Hospital
mi
from
Vancouver,
SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC)
A Phase 2 Study of SGI-110 in the Treatment of Advanced Hepatocellular Carcinoma (HCC) Subjects Who Failed Prior Treatment With Sorafenib
Status: Enrolling
Updated: 12/28/2015
University of British Columbia and Vancouver General Hospital
mi
from
Vancouver,
Click here to add this to my saved trials
Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer
Phase II Study Of Neo-Adjuvant Paclitaxel, Estramustine And Carboplatin (TEC) Plus Androgen Ablation Prior To Radiation Therapy In Patients With Poor Prognosis Localized Prostate Cancer
Status: Enrolling
Updated:  12/28/2015
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
mi
from
Washington,
Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer
Phase II Study Of Neo-Adjuvant Paclitaxel, Estramustine And Carboplatin (TEC) Plus Androgen Ablation Prior To Radiation Therapy In Patients With Poor Prognosis Localized Prostate Cancer
Status: Enrolling
Updated: 12/28/2015
Lombardi Comprehensive Cancer Center at Georgetown University Medical Center
mi
from
Washington,
Click here to add this to my saved trials
Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer
Phase II Study Of Neo-Adjuvant Paclitaxel, Estramustine And Carboplatin (TEC) Plus Androgen Ablation Prior To Radiation Therapy In Patients With Poor Prognosis Localized Prostate Cancer
Status: Enrolling
Updated:  12/28/2015
Walter Reed Army Medical Center
mi
from
Washington,
Chemotherapy, Hormone Therapy, and Radiation Therapy in Treating Patients With Locally Advanced Prostate Cancer
Phase II Study Of Neo-Adjuvant Paclitaxel, Estramustine And Carboplatin (TEC) Plus Androgen Ablation Prior To Radiation Therapy In Patients With Poor Prognosis Localized Prostate Cancer
Status: Enrolling
Updated: 12/28/2015
Walter Reed Army Medical Center
mi
from
Washington,
Click here to add this to my saved trials